Authors

Latest:

Dr. Wolchok on Weighing Risk and Benefit of Nivolumab/Ipilimumab Combo in Melanoma

Jedd D. Wolchok, MD, PhD, chief, Melanoma and Immunotherapeutics Service, Memorial Sloan Kettering Cancer Center, discusses weighing the overall survival (OS) benefit with the increased risk of toxicities seen with the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) in treatment-naïve patients with advanced melanoma.

Jeff Geschwind, MD

Latest:

Dr. Geschwind on Locoregional Therapy for Patients With Liver Cancer

Jeff Geschwind, MD, professor and chairman, Radiology and Biomedical Imaging, Yale Cancer Center, discusses locoregional treatment options for patients with hepatocellular carcinoma (HCC).

Jeff Geschwind, MD, Johns Hopkins

Jeff Michalski, MD

Latest:

Dr. Michalski on Minimizing Long-Term Consequences of Radiation

Jeff Michalski, MD, professor, vice chair of Radiation Oncology, Washington University School of Medicine, Siteman Cancer Center explains the importance of minimizing the long-term consequences of radiation.

Jeff P. Sharman, MD

Latest:

Dr. Sharman on the Challenges of Adjusting Treatment Based on MRD Status in CLL

Jeff P. Sharman, MD, discusses the challenges of adjusting treatments based on minimal residual disease status in high-risk chronic lymphocytic leukemia.

Jeff Prescott, PharmD

Latest:

TechSectors: Mobile/Wireless: iPhone 3G, the First 30 Days

Last year, I promised myself not to accept waiting in line for the iPhone "classic" and was fortunate enough to sneak into an Apple store late one night to purchase one without any hassles.

Jeff Sharman, MD

Latest:

Dr. Sharman on 5-Year Data From the Elevate CLL TN Trial in CLL

Jeff Sharman, MD, discusses 5-year follow-up data from the phase 3 Elevate CLL TN trial in treatment-naïve patients with chronic lymphocytic leukemia.

Jeff Yorio, MD

Latest:

Dr. Yorio on the Safety of Targeted Therapies in BRAF-Mutated Melanoma

Jeff Yorio, MD, discusses adverse effects associated with targeted agents and combinations in BRAF-mutated melanoma.

Jeffery C. Ward, MD, Swedish Cancer Institute

Jeffery S. Weber, MD, PhD

Latest:

Dr. Weber on the Toxicities Associated With Immunotherapy in Lung Cancer

Jeffrey S. Weber, MD, PhD, discusses the toxicities associated with immunotherapy in lung cancer.

Jeffrey A. Gudin,

Jeffrey A. Gudin, M

Jeffrey A. Gudin, MD,

Jeffrey A. Sosman, MD

Latest:

Dr. Sosman on the Mechanism of Action of Ipilimumab

Jeffrey A. Sosman, MD, professor of medicine, Director, Melanoma and Tumor Immunotherapy Program, Vanderbilt University School of Medicine, Vanderbilt-Ingram Cancer Center, describes the mechanism of action of ipilimumab in patients with melanoma.

Jeffrey A. Sosman, MD, Vander

Jeffrey Crawford, MD

Latest:

Dr Crawford on the Evolving Role of Active Surveillance in Prostate Cancer

E. David Crawford, MD, discusses the evolving role of active surveillance in patients with prostate cancer.

Jeffrey D. Bradley, MD

Latest:

Dr. Bradley on Radiation Therapy in Lung Cancer

Jeffrey D. Bradley, MD, Professor, Radiation Oncology, Washington University School of Medicine in St. Louis, discusses ongoing research involving radiation therapy for lung cancer.

Jeffrey E. Lancet, MD

Latest:

Dr. Lancet on CPX-351 in Elderly Patients With AML

Jeffrey E. Lancet, MD, medical oncologist, Moffitt Cancer Center, discusses results of a randomized phase III study comparing the efficacy of CPX-351 (Vyxeos) versus daunorubicin (7+3) plus cytarabine in older patients with newly diagnosed, high-risk acute myeloid leukemia (AML).

Jeffrey E. Lee, MD

Latest:

Radiation Dose Escalation to the Tumor-Arterial Interface of Locally Advanced and Borderline Resectable Pancreatic Cancer

An integrated boost with conventional fractionation to the tumor-arterial interface is unlikely to lead to downstaging in borderline resectable and locally advanced pancreatic cancer.

Jeffrey Humphrey, MD

Latest:

Dr. Humphrey on Mogamulizumab for Cutaneous T-Cell Lymphoma

Jeffrey Humphrey, MD, president, Kyowa Hakko Kirin Pharma, Inc., discusses the benefits of mogamulizumab for the treatment of cutaneous T-cell lymphoma.